Prognostic Significance of MicroRNA-135 in Patients with Digestive System Cancers: a Systematic Review and Meta-analysis

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2019 Dec 6

PMID 31803920

Citations 3

Authors

Ce Chao

Chen Sang

Min Wang

Zijin Wang

Yanfei Li

Guanghua Luo

Xiaoying Zhang

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNA-135 (miR-135) is a well-known non-coding RNA that has been demonstrated to participate in tumorigenesis and cancer development; however, the clinical prognostic value of miR-135 in digestive system cancers remains controversial. This meta-analysis aims to explore the potential value of miR-135 as a prognostic marker for digestive system cancers.

Methods: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible articles published before 31 August 2019. Stata 12.0 software was used to analyze the overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) rates to access the prognostic value of miR-135 in digestive system cancers. We then used The Cancer Genome Atlas (TCGA) datasets to validate the meta-analysis results. Results A total of 1470 patients from 17 studies were included in this meta-analysis. The pooled results showed that enhanced miR-135 expression was significantly associated with poor OR (hazard ratio (HR): 1.790; 95% confidence interval (95% CI): 1.577-2.031; P=0.000), DFS (HR: 1.482; 95% CI: 0.914-2.403; P=0.110), and RFS (HR: 3.994; 95% CI: 1.363-11.697; P=0.012) in digestive system cancers. A sensitivity analysis confirmed the reliability of our findings, and no significant publication bias was observed.

Conclusion: MiR-135 can be used as a novel biomarker for patients with digestive system cancers. We look forward to future large-scale clinical studies that will investigate the prognostic value of miR-135.

Citing Articles

The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance.

Tavakoli Pirzaman A, Alishah A, Babajani B, Ebrahimi P, Sheikhi S, Moosaei F Technol Cancer Res Treat. 2024; 23:15330338241239188.

PMID: 38634139 PMC: 11025440. DOI: 10.1177/15330338241239188.

A review on the importance of miRNA-135 in human diseases.

Kadkhoda S, Eslami S, Hussen B, Ghafouri-Fard S Front Genet. 2022; 13:973585.

PMID: 36147505 PMC: 9486161. DOI: 10.3389/fgene.2022.973585.

Clinical value of miR-135 and miR-20a combined with multi-detector computed tomography in the diagnosis of gastric cancer.

Han W, Bu X, Liu Y, Liu F, Ren Y, Cui Y World J Surg Oncol. 2021; 19(1):283.

PMID: 34537058 PMC: 8449899. DOI: 10.1186/s12957-021-02395-z.

References

Zhang Y, Ren S, Yuan F, Zhang K, Fan Y, Zheng S . miR-135 promotes proliferation and stemness of oesophageal squamous cell carcinoma by targeting RERG. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):1210-1219. DOI: 10.1080/21691401.2018.1483379. View

Wang Z, Zhang J, Zhang Z, Jiang Y, Li M, Li Q . Prognostic value of miR-17-5 p in gastrointestinal cancers: a systematic review and meta-analysis. Onco Targets Ther. 2018; 11:5991-5999. PMC: 6157989. DOI: 10.2147/OTT.S157670. View

Yang L, Jiang J . GAS5 Regulates RECK Expression and Inhibits Invasion Potential of HCC Cells by Sponging miR-135b. Biomed Res Int. 2019; 2019:2973289. PMC: 6348854. DOI: 10.1155/2019/2973289. View

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N . Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96(6):434-42. PMC: 7713993. DOI: 10.1093/jnci/djh075. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Jiang D, Zhou B, Xiong Y, Cai H . miR-135 regulated breast cancer proliferation and epithelial-mesenchymal transition acts by the Wnt/β-catenin signaling pathway. Int J Mol Med. 2019; 43(4):1623-1634. PMC: 6414157. DOI: 10.3892/ijmm.2019.4081. View

Wetterslev J, Thorlund K, Brok J, Gluud C . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2007; 61(1):64-75. DOI: 10.1016/j.jclinepi.2007.03.013. View

von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B . High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer. 2017; 17(1):60. PMC: 5242004. DOI: 10.1186/s12885-017-3053-7. View

Zhou Y, Li S, Li J, Wang D, Li Q . Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2017; 42(4):1431-1446. DOI: 10.1159/000479207. View

10.

Zhang Q, Wang Q, Sun W, Gao F, Liu L, Cheng L . Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis. Biomed Res Int. 2019; 2018:6124927. PMC: 6286746. DOI: 10.1155/2018/6124927. View

11.

Petracco R, Grechukhina O, Popkhadze S, Massasa E, Zhou Y, Taylor H . MicroRNA 135 regulates HOXA10 expression in endometriosis. J Clin Endocrinol Metab. 2011; 96(12):E1925-33. PMC: 3232619. DOI: 10.1210/jc.2011-1231. View

12.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

13.

Li C, Zhang W, Xiang J, Wang X, Li J, Wang J . Identification of microRNAs as novel biomarkers for esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas (TCGA) and bioinformatics. Chin Med J (Engl). 2019; 132(18):2213-2222. PMC: 6797152. DOI: 10.1097/CM9.0000000000000427. View

14.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

15.

Scarpa M, Noaro G, Saadeh L, Cavallin F, Cagol M, Alfieri R . Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma. World J Surg. 2014; 39(2):424-32. DOI: 10.1007/s00268-014-2835-1. View

16.

Kawaguchi T, Komatsu S, Ichikawa D, Tsujiura M, Takeshita H, Hirajima S . Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers. Int J Mol Sci. 2016; 17(9). PMC: 5037738. DOI: 10.3390/ijms17091459. View

17.

Gao S, Zhou F, Zhao C, Ma Z, Jia R, Liang S . Gastric cardia adenocarcinoma microRNA profiling in Chinese patients. Tumour Biol. 2016; 37(7):9411-22. DOI: 10.1007/s13277-016-4824-5. View

18.

Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G . Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017; 17(1):737. PMC: 5679342. DOI: 10.1186/s12885-017-3738-y. View

19.

Ruopp M, Perkins N, Whitcomb B, Schisterman E . Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 2008; 50(3):419-30. PMC: 2515362. DOI: 10.1002/bimj.200710415. View

20.

Gaedcke J, Grade M, Camps J, Sokilde R, Kaczkowski B, Schetter A . The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 2012; 18(18):4919-30. PMC: 6298229. DOI: 10.1158/1078-0432.CCR-12-0016. View